An investigation on behalf of investors in Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) shares over potential wrongdoing at Bellicum Pharmaceuticals Inc was announced.
San Diego, CA -- (SBWIRE) -- 06/03/2019 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Bellicum Pharmaceuticals Inc.
Investors who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Bellicum Pharmaceuticals directors breached their fiduciary duties and caused damage to the company and its shareholders.
On February 6, 2018, a lawsuit was filed against Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) over alleged violations of Federal Securities Laws. The plaintiff claims that between May 8, 2017, and January 30, 2018, the Defendants made false and/or misleading statements and/or failed to disclose that a substantial undisclosed risk of encephalopathy was associated with the Company's lead product candidate BPX-501, and that as a result of the foregoing, Bellicum's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels